

Special Issue

Understanding Immune Responses to COVID-19 Vaccines

Message from the Guest Editor

The availability of safe and effective vaccines for the SARS-CoV-2 virus proved crucial in containing and mitigating the COVID-19 pandemic globally. Despite the significant work conducted by the scientific and social communities and the great results achieved in containing the disease, there is a long way to go. Several critical biological and clinical issues must be addressed, including the emergence of variants and the short duration of protective immunity. These issues are not the only critical areas of inquiry, and questions relating to patients with disabilities, patients in critical age groups, and other frail individuals are yet to be adequately addressed. To discuss and share the latest research results and develop new ideas, we are launching a Special Issue, entitled 'Understanding Immune Responses to COVID-19 Vaccines' which is actually the 2nd edition of 'Immune Responses to COVID-19 Vaccines'.

Guest Editor

Dr. Federico De Marco

Department of RDAT, the Regina Elena National Cancer Institute
IRCCS, Via Elio Chianesi 53, 00144 Rome, Italy

Deadline for manuscript submissions

closed (31 July 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/191350

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).